🎉 M&A multiples are live!
Check it out!

CytomX Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for CytomX Therapeutics and other public comps.

See CytomX Therapeutics Valuation Multiples

CytomX Therapeutics Overview

About CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.


Founded

2010

HQ

United States of America
Employees

122

Website

cytomx.com

Financials

LTM Revenue $112M

LTM EBITDA -$11.1M

EV

-$41.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CytomX Therapeutics Financials

CytomX Therapeutics has a last 12-month revenue of $112M and a last 12-month EBITDA of -$11.1M.

In the most recent fiscal year, CytomX Therapeutics achieved revenue of $101M and an EBITDA of -$4.3M.

CytomX Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CytomX Therapeutics valuation multiples based on analyst estimates

CytomX Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $53.2M $101M $116M $112M XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$98.9M -$4.3M -$6.4M -$11.1M XXX
EBITDA Margin -186% -4% -6% -10% XXX
Net Profit -$83.6M -$99.3M -$0.6M XXX XXX
Net Margin -157% -98% 0% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

CytomX Therapeutics Stock Performance

As of February 10, 2025, CytomX Therapeutics's stock price is $1.

CytomX Therapeutics has current market cap of $65.7M, and EV of -$41.3M.

See CytomX Therapeutics trading valuation data

CytomX Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$41.3M $65.7M XXX XXX XXX XXX $-0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CytomX Therapeutics Valuation Multiples

As of February 10, 2025, CytomX Therapeutics has market cap of $65.7M and EV of -$41.3M.

CytomX Therapeutics's trades at -0.4x LTM EV/Revenue multiple, and 3.7x LTM EBITDA.

Analysts estimate CytomX Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CytomX Therapeutics and 10K+ public comps

CytomX Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$41.3M XXX XXX XXX
EV/Revenue -0.4x XXX XXX XXX
EV/EBITDA 6.4x XXX XXX XXX
P/E -16.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CytomX Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CytomX Therapeutics Valuation Multiples

CytomX Therapeutics's NTM/LTM revenue growth is -32%

CytomX Therapeutics's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, CytomX Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CytomX Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CytomX Therapeutics and other 10K+ public comps

CytomX Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 14% XXX XXX XXX XXX
EBITDA Margin -6% XXX XXX XXX XXX
EBITDA Growth 49% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -38% XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 30% XXX XXX XXX XXX
R&D Expenses to Revenue 77% XXX XXX XXX XXX
Opex to Revenue 106% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

CytomX Therapeutics Public Comps

See valuation multiples for CytomX Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CytomX Therapeutics M&A and Investment Activity

CytomX Therapeutics acquired  XXX companies to date.

Last acquisition by CytomX Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . CytomX Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CytomX Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CytomX Therapeutics

When was CytomX Therapeutics founded? CytomX Therapeutics was founded in 2010.
Where is CytomX Therapeutics headquartered? CytomX Therapeutics is headquartered in United States of America.
How many employees does CytomX Therapeutics have? As of today, CytomX Therapeutics has 122 employees.
Who is the CEO of CytomX Therapeutics? CytomX Therapeutics's CEO is Dr. Sean A. McCarthy, D.Phil..
Is CytomX Therapeutics publicy listed? Yes, CytomX Therapeutics is a public company listed on NAS.
What is the stock symbol of CytomX Therapeutics? CytomX Therapeutics trades under CTMX ticker.
When did CytomX Therapeutics go public? CytomX Therapeutics went public in 2015.
Who are competitors of CytomX Therapeutics? Similar companies to CytomX Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of CytomX Therapeutics? CytomX Therapeutics's current market cap is $65.7M
What is the current revenue of CytomX Therapeutics? CytomX Therapeutics's last 12-month revenue is $112M.
What is the current EBITDA of CytomX Therapeutics? CytomX Therapeutics's last 12-month EBITDA is -$11.1M.
What is the current EV/Revenue multiple of CytomX Therapeutics? Current revenue multiple of CytomX Therapeutics is -0.4x.
What is the current EV/EBITDA multiple of CytomX Therapeutics? Current EBITDA multiple of CytomX Therapeutics is 3.7x.
What is the current revenue growth of CytomX Therapeutics? CytomX Therapeutics revenue growth between 2023 and 2024 was 14%.
Is CytomX Therapeutics profitable? Yes, CytomX Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.